OXiGENE to Present at BIO CEO and Investor Conference on February 12, 2008 WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 5, 2008--Regulatory News: OXiGENE, Inc. (NASDAQ: OXGN) (XSSE: OXGN), a clinical stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that President and CEO Richard Chin, M.D., will present a corporate overview and update at the BIO CEO and Investor Conference on Tuesday, February 12, at 10:15 a.m. EST (7:15 a.m. PST), in the Waldorf-Astoria hotel's Norse Suite in New York City, NY. A live and archived webcast of the presentation can be accessed for 30 days following the presentation under the Investor Center tab at www.oxigene.com. About OXiGENE, Inc. OXiGENE is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat cancer and eye diseases. The Company's major focus is the clinical advancement of drug candidates that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. OXiGENE is dedicated to leveraging its intellectual property position and therapeutic development expertise to bring life saving and enhancing medicines to patients. OXiGENE, Inc. Michelle Edwards, 415-315-9413 Investor Relations medwards@oxigene.com
OXiGENE to Present at BIO CEO and Investor Conference on February 12, 2008
| Source: Oxigene, Inc.